How enoxaparin underdosing and sex contribute to achieving therapeutic anti-Xa levels
Recent publication
Researchers at Karl Landsteiner University in Austria conducted a retrospective, multicentre study to determine the dose of enoxaparin administered to patients with atrial fibrillation and acute ischaemic stroke. Enoxaparin has a blood-thinning effect and is used to prevent thrombosis. In the study, the recommended dose was compared with the dose actually administered and the effects of the differences on anti-Xa levels were documented. Anti-Xa levels correlate with clotting activity and are used to monitor anticoagulant drug therapy. The study, led by Dr Alexander Tinchon from the Division of Neurology in St. Pölten University Hospital, was made freely available in the journal Frontiers in Pharmacology thanks to open access funding from Karl Landsteiner University.
Tinchon, A, Brait, J, Klee, S, Graichen, U, Baumgartner, C, Friedrich, O, Freydl, E, Oberndorfer, S, Struhal, W, Hain, B, Waiß, C & Stoiber, D 2024, 'How enoxaparin underdosing and sex contribute to achieving therapeutic anti-Xa levels', Frontiers in Pharmacology, vol. 15. https://doi.org/10.3389/fphar.2024.1377232
OA Dr. Alexander Tinchon
Division of Neurology (University Hospital St. Pölten)
Dr. Christian Baumgartner MSc PhD
Institute of Laboratory Medicine (Central Laboratory) (University Hospital St. Pölten)
OÄ Dr. Elisabeth Freydl
Division of Neurology (University Hospital St. Pölten)
Prim. Univ.-Prof. PD Dr. Stefan Oberndorfer FEAN
Division of Neurology (University Hospital St. Pölten)
Prim. Univ.-Prof. PD Dr. Walter Struhal MSc FEAN
Division of Neurology (University Hospital Tulln)
OÄ Dr. Barbara Hain
Division of Neurology (University Hospital Tulln)
OA Dr. Christoph Waiß
Division of Neurology (University Hospital St. Pölten)